International Journal of Psychiatry in Clinical Practice最新文献_第7页

Association between heart rate variability and emotion dysregulation in adolescents with non-suicidal self-injury. 非自杀性自伤青少年心率变异性与情绪失调的关系。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-08-30 DOI: 10.1080/13651501.2025.2551772

Maya Aulya Saputri, Andrian Fajar Kusumadewi, Kamilaturrizqi Sakinah

{"title":"Association between heart rate variability and emotion dysregulation in adolescents with non-suicidal self-injury.","authors":"Maya Aulya Saputri, Andrian Fajar Kusumadewi, Kamilaturrizqi Sakinah","doi":"10.1080/13651501.2025.2551772","DOIUrl":"10.1080/13651501.2025.2551772","url":null,"abstract":"Introduction: Non-suicidal self-injury (NSSI) is a strong predictor of increased future suicidal ideation and risk. The highest prevalence of NSSI is in adolescents. NSSI is performed as a maladaptive response to emotion regulation distress when facing an intense negative emotional load. One of the physiological markers of Emotion Dysregulation (ED) can be measured quantitatively through changes in Heart Rate Variability (HRV).Objective: The purpose of this review is to provide an overview about studies on HRV and ED in adolescents with NSSI to shed light on potential associations and to identify prospective approaches for future studies.Method: Literature was searched through Pubmed using Heart Rate Variability (HRV), Emotion Dysregulation (ED), and Non Suicidal Self-Injury (NSSI) as the keywords. Inclusion criteria were full-text journal articles in English or Indonesian within the last 10 years.Results: Studies show that ED in certain mental disorders has been associated with HRV changes through the autonomic nervous system imbalance pathway. For individuals with ED, NSSI may serve certain perceived benefits, reinforcing its repetition whenever adverse events are encountered.Conclusions: ED in adolescents with NSSI can be observed through HRV reduction. This approach may help improve adolescent mental health by reducing NSSI and preventing suicidal tendencies.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"193-198"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of patients starting treatment with second-generation antipsychotics: insights from a European retrospective real-world analysis. 开始使用第二代抗精神病药物治疗的患者的管理：来自欧洲回顾性现实世界分析的见解。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-09-29 DOI: 10.1080/13651501.2025.2564789

Giancarlo Cerveri, Claudio Mencacci, Alessandro Ruggieri, Valeria Pegoraro, Riccardo Cipelli, Clara Bagatin, Simona Barzaghi, Alessandro Lovera, Irene Gabarda Inat, Alessandro Comandini, Agnese Cattaneo

{"title":"Management of patients starting treatment with second-generation antipsychotics: insights from a European retrospective real-world analysis.","authors":"Giancarlo Cerveri, Claudio Mencacci, Alessandro Ruggieri, Valeria Pegoraro, Riccardo Cipelli, Clara Bagatin, Simona Barzaghi, Alessandro Lovera, Irene Gabarda Inat, Alessandro Comandini, Agnese Cattaneo","doi":"10.1080/13651501.2025.2564789","DOIUrl":"10.1080/13651501.2025.2564789","url":null,"abstract":"Objectives: Understanding real-life management of mental health disorders is crucial for enabling effective social and healthcare interventions. This retrospective real-world study investigated differences in the management of young adults (<30 years) and adults (≥30 years) starting treatment with second-generation antipsychotics (SGAs) in Italy, Spain and Poland.Methods: Patients' characteristics, treatment and safety profile and healthcare resource utilisation were analysed from general practitioners' and psychiatrists' electronic medical records and from pharmacy prescription records. The main analysis was stratified by age, but stratification by SGA molecule and a focus on subjects with schizophrenia were also provided.Results: A total of 530,587 subjects started treatment with SGAs. Throughout data sources, young adults accounted for from 17.8% to 30.2%; women were more represented among adults, who also had higher proportions of comorbid conditions. Young adults showed higher frequencies of switches (from 4.7% to 11.0% for young adults and from 2.9% to 8.6% for adults) and add-ons (from 2.5% to 5.6% for young adults and from 1.7% to 5.0% for adults) and exhibited slightly better adherence/persistence with the initial SGA.Conclusions: Distinct management behaviours were identified depending on age. A nuanced approach integrating tailored therapeutic strategies is needed to optimise long-term outcomes for patients requiring treatment with SGAs.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"258-271"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between the Montgomery-Åsberg Depression Rating Scale and Sheehan Disability Scale in patients with bipolar depressive episodes. Montgomery-Åsberg抑郁评定量表与Sheehan残疾评定量表在双相抑郁发作患者中的关系。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1080/13651501.2025.2560353

Hidehiro Oshibuchi, Hiroshi Nakamura, Kazumasa Yoshida, Jun Ishigooka, Katsuji Nishimura

{"title":"Relationship between the Montgomery-Åsberg Depression Rating Scale and Sheehan Disability Scale in patients with bipolar depressive episodes.","authors":"Hidehiro Oshibuchi, Hiroshi Nakamura, Kazumasa Yoshida, Jun Ishigooka, Katsuji Nishimura","doi":"10.1080/13651501.2025.2560353","DOIUrl":"10.1080/13651501.2025.2560353","url":null,"abstract":"Objective: To examine the relationship between depressive symptoms and daily functioning among patients with bipolar depression using the Montgomery-Åsberg Depression Rating Scale (MADRS) and Sheehan Disability Scale (SDS).Methods: A post-hoc analysis was conducted using data from a placebo-controlled study of lurasidone involving 399 patients with bipolar depression. Pearson's correlation coefficient was used to analyse the correlation between the MADRS and SDS total scores. Receiver operating characteristic (ROC) analysis determined the MADRS cut-off score for adequate functional improvement, defined as all SDS subscale scores ≤2.Results: The MADRS and SDS scores were positively correlated (r = 0.764). The ROC analysis yielded a MADRS cut-off score of 15.5 for adequate functional improvement with 86.9% sensitivity and 75.9% specificity. The wide distribution of the relationship observed between symptoms and functioning indicated diversity in treatment responsiveness in bipolar depression.Conclusions: Depressive symptoms and daily functioning are correlated; however, this relationship is not straightforward, highlighting the need for evaluating symptoms and functioning separately. Importantly, direct application of the statistical MADRS threshold in clinical practice may be inappropriate for estimating SDS-based functioning. Further research is needed to establish norms linking levels of symptoms and functioning in bipolar depression.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"272-279"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Asenapine for aggressive behaviours in psychiatric disorders: a systematic review of efficacy and real-world effectiveness. 阿塞那平治疗精神疾病中的攻击行为：疗效和现实世界有效性的系统综述。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-09-18 DOI: 10.1080/13651501.2025.2560357

Mauro Scala, Giuseppe Fanelli, Chiara Fabbri, Alessandro Serretti

{"title":"Asenapine for aggressive behaviours in psychiatric disorders: a systematic review of efficacy and real-world effectiveness.","authors":"Mauro Scala, Giuseppe Fanelli, Chiara Fabbri, Alessandro Serretti","doi":"10.1080/13651501.2025.2560357","DOIUrl":"10.1080/13651501.2025.2560357","url":null,"abstract":"Background: Clinical decision-making for the pharmacological treatment of aggressive behaviour in psychiatry remains challenging. Asenapine, a second-generation antipsychotic with a higher affinity for dopamine D4 than for D2 receptors, may become a treatment option, although this remains to be demonstrated.Methods: A systematic search was conducted across biomedical databases according to PRISMA Reporting Items for Systematic Review. We aimed to examine the efficacy and effectiveness of asenapine in the management of aggressive behaviours including psychomotor agitation, hostility, irritability, anger, impulsivity, self-harm, behavioural disinhibition, as well as physical and verbal aggression, across psychiatric disorders.Results: Of the 12 studies included, four reported asenapine's efficacy in aggressive behaviours compared to placebo, and five described the effectiveness in uncontrolled settings. Three studies found no advantages over olanzapine. Major evidence supports asenapine's efficacy in reducing psychomotor agitation and hostility, with benefits independent of its anti-manic and antipsychotic effects.Conclusion: Asenapine may be a viable option for the treatment of psychomotor agitation and hostility, although more head-to-head trials are needed to clarify its efficacy relative to other antipsychotics. Since the evidence of efficacy in other aggressive domains and diagnoses is still limited, clinicians should primarily consider the tolerability profile to guide their prescription.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"179-192"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

mRNA levels of HPA axis mediators in drug-naïve, first episode psychosis patients before and after antipsychotic treatment. drug-naïve首发精神病患者抗精神病药物治疗前后HPA轴介质mRNA水平的变化。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-08-22 DOI: 10.1080/13651501.2025.2549306

Daniela Theodoridou, Christos-Orestis Tsiantis, Georgios Markozannes, Vasiliki Chondrou, Angeliki-Maria Vlaikou, Andreas Karampas, Georgios Georgiou, Argyro Sgourou, Michaela D Filiou, Maria Syrrou, Petros Petrikis

{"title":"mRNA levels of HPA axis mediators in drug-naïve, first episode psychosis patients before and after antipsychotic treatment.","authors":"Daniela Theodoridou, Christos-Orestis Tsiantis, Georgios Markozannes, Vasiliki Chondrou, Angeliki-Maria Vlaikou, Andreas Karampas, Georgios Georgiou, Argyro Sgourou, Michaela D Filiou, Maria Syrrou, Petros Petrikis","doi":"10.1080/13651501.2025.2549306","DOIUrl":"10.1080/13651501.2025.2549306","url":null,"abstract":"Objective: In this study we assessed if the genetic variation and gene expression of stress-associated mediators contribute to First Episode in Psychosis (FEP) and explored how mRNA levels of Hypothalamus-Pituitary-Adrenal (HPA) axis mediators change after treatment with antipsychotics.Methods: We genotyped FKBP5 and SLC6A4 variants and associated them with Positive and Negative Syndrome Scale (PANSS). We assessed the mRNA levels of HPA axis mediators in FEPs before and after treatment with antipsychotics, while comparing them to matched controls.Results: FKPB5 rs1360780 T allele was associated with higher and lower scores in the PANSS-Negative and PANSS-General scales. FKPB5 rs3800373 C allele carriers had lower risk to suffer from FEP. FEP individuals had decreased NR3C2 and increased FKBP5 and GILZ/TSC22D3 mRNA levels. After treatment, the mRNA levels of GILZ/TSC22D3 were comparable to those of the control group. Higher FKBP5 and GILZ expression levels were associated with higher risk for FEP occurrence and the difference in FKBP5 and GILZ expression levels before and after treatment with antipsychotics was associated with the difference in PANSS-T scores.Conclusion: The data above, pinpoint towards a dysregulated HPA axis, that putatively affects the outcome and symptomatology of a First Episode in Psychosis.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"209-221"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical validation of a Chinese translation of the parent tic questionnaire. 父母抽噎问卷中文翻译的临床验证。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-09-11 DOI: 10.1080/13651501.2025.2553313

Qinyu Li, Yingying Cai, Rong Chen, Duan Lin, Jiqiang Xie, Yanting Lu, Yajun Tang, Xiumei Liu

{"title":"Clinical validation of a Chinese translation of the parent tic questionnaire.","authors":"Qinyu Li, Yingying Cai, Rong Chen, Duan Lin, Jiqiang Xie, Yanting Lu, Yajun Tang, Xiumei Liu","doi":"10.1080/13651501.2025.2553313","DOIUrl":"10.1080/13651501.2025.2553313","url":null,"abstract":"Background: The Yale Global Tic Severity Scale (YGTSS), although extensively utilised in China for evaluating tic disorders (TD), relies exclusively on clinician-administered assessments. At present, no parent-report instruments validated in the Chinese context are available for assessing tics. The Parent Tic Questionnaire (PTQ), originally developed as the first parent-rated tool for TD symptom evaluation, has yet to undergo validation in any Asian language.Methods: A total of 414 children and adolescents aged 2-16 years with a TD diagnosis were recruited. The PTQ, YGTSS, Conners' Parent Rating Scale (CPRS-48) and Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) were administered to examine the psychometric characteristics of the PTQ.Results: Cronbach's alpha coefficients for the PTQ motor, vocal and total tic subscales were 0.789, 0.821 and 0.849, indicating satisfactory internal consistency. Strong correlations were observed between PTQ total scores and YGTSS scores. A cut-off score of 14 on the PTQ emerged as the most appropriate threshold for differentiating between mild and moderate TD. The content validity index further demonstrated high validity for the Chinese PTQ.Conclusions: The validated Chinese version of the PTQ exhibits robust psychometric properties and provides clinically informative metrics for tic severity stratification, establishing a foundation for score standardisation in routine assessments.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"229-239"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating the effect of exercise on clinical symptoms, cognitive performance, and quality of life in schizophrenia patients treated with clozapine. 研究运动对氯氮平治疗的精神分裂症患者临床症状、认知表现和生活质量的影响。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-08-05 DOI: 10.1080/13651501.2025.2542785

İsmail Koç, Ebru Akbuğa Koç

{"title":"Investigating the effect of exercise on clinical symptoms, cognitive performance, and quality of life in schizophrenia patients treated with clozapine.","authors":"İsmail Koç, Ebru Akbuğa Koç","doi":"10.1080/13651501.2025.2542785","DOIUrl":"10.1080/13651501.2025.2542785","url":null,"abstract":"Background: This prospective study aims to investigate the effects of exercise on clinical symptoms, cognitive performance, and quality of life in schizophrenia patients treated with clozapine.Methods: Fifty-six (n = 56) participants were completed as the physical exercise group (PEG) (n = 28) and control group (CG) (n = 28). The PEG participated in an exercise program lasting 30 min, three times a week, for 12 weeks, in addition to a routine ergotherapy programme. The CG did not receive any treatment other than ergotherapy programme. Sociodemographic characteristics, Positive and Negative Syndrome Scale (PANNS), Brief Psychiatric Rating Scale (BPRS), Montreal Cognitive Assessment (MOCA), and The World Health Organisation Quality of Life (WHQOL-BREF) evaluated at baseline and after 12 weeks for both groups.Results: After intervention, a statistically significant increase was observed in the MOCA and the psychological health sub-parameter of WHQOL-BREF in the PEG (p ≤ 0.05). According to the intergroup change analysis, the changes in the cognitive performance and psychological health sub-parameter of quality-of-life scores were significantly higher in the PEG than in the CG (p ≤ 0.05).Conclusion: The demonstrated improvement in cognitive performance and psychological health in patients with schizophrenia treated with Clozapine through physical exercise strongly advocates for the inclusion of structured exercise programs in comprehensive treatment plans.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"199-208"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis. 参与减肥试验的肥胖或超重稳定双相情感障碍患者暴食障碍的特征-事后分析。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-08-24 DOI: 10.1080/13651501.2025.2549307

Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Francisco Romo-Nava, Susan L McElroy

{"title":"Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.","authors":"Anna I Guerdjikova, Thomas J Blom, Nicole Mori, Francisco Romo-Nava, Susan L McElroy","doi":"10.1080/13651501.2025.2549307","DOIUrl":"10.1080/13651501.2025.2549307","url":null,"abstract":"Objective: To inform clinical decision-making for patients with obesity, binge eating disorder (BED) and bipolar disorder (BD), we compared individuals with BED and those without BED who participated in a randomised controlled trial (RCT) of liraglutide for weight loss in stable BD with obesity.Methods: This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.Results: Compared to those without BED (N = 43), participants with BED (N = 17) had a higher body mass index (BMI) and higher HbA1c levels, were taking more antidepressants, and had higher Binge Eating Scale (BES) scores and Three Factor Eating Questionnaire (TFEQ) disinhibition of eating and hunger subscale scores. Among the 17 BED participants, liraglutide (N = 9) and placebo (n = 8) were associated with similar reductions in percent change of body weight and BES scores. Liraglutide was well tolerated, but the BED group experienced significantly more nausea/vomiting (p = .04), constipation (p = .02) and anxiety (p = .02).Conclusions: RCTs are warranted to enrich the pharmacological armamentarium available to treat such complex patients.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"280-283"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy of metformin in counteracting olanzapine-induced hyperprolactinemia: an open-label prospective study. 二甲双胍对抗奥氮平诱导的高泌乳素血症的疗效：一项开放标签前瞻性研究。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-08-28 DOI: 10.1080/13651501.2025.2550501

Kah Kheng Goh, Tzu-Hua Wu, Chun-Hsin Chen, Po-Yu Chen, Mong-Liang Lu

{"title":"The efficacy of metformin in counteracting olanzapine-induced hyperprolactinemia: an open-label prospective study.","authors":"Kah Kheng Goh, Tzu-Hua Wu, Chun-Hsin Chen, Po-Yu Chen, Mong-Liang Lu","doi":"10.1080/13651501.2025.2550501","DOIUrl":"10.1080/13651501.2025.2550501","url":null,"abstract":"Objectives: Prolactin elevation is a common adverse effect of antipsychotic medications. The study aimed to explore the potential of metformin in managing olanzapine-induced hyperprolactinaemia.Methods: A prospective study was designed to investigate the changes in prolactin levels over an eight-week metformin treatment. Thirty-one patients with schizophrenia (aged 18-60 years) on a stable dose of olanzapine for at least three months were enrolled. Participants received metformin at 1500 mg/day for eight weeks. Prolactin levels and metabolic parameters were measured at baseline and at weeks 2, 4, 6, and 8.Results: After eight weeks of metformin intervention, prolactin levels significantly decreased from 39.7 ± 20.0 ng/mL at baseline to 35.7 ± 15.7 ng/mL (p = 0.005) with a moderate effect size (Cohen's d = 0.545). Reductions in prolactin levels correlated positively with baseline prolactin levels (r = 0.72, p < 0.001) and baseline glucose levels (r = 0.47, p = 0.008). Body weight, BMI, insulin level, glucose level, and insulin resistance significantly decreased after metformin treatment.Conclusion: Although participants experienced mild hyperprolactinaemia, metformin effectively counteracted prolactin elevation and improved metabolic parameters. This study highlights metformin's potential to mitigate antipsychotic-induced adverse effect.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"222-228"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metformin usage in the treatment of risperidone induced hyperprolactinemia in an adolescent patient with bipolar disorder type 1: a case report. 二甲双胍用于治疗利培酮诱导的1型青少年双相情感障碍患者的高泌乳素血症：1例报告。

IF 2.7 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2025-11-01 Epub Date: 2025-09-17 DOI: 10.1080/13651501.2025.2563341

Ece Topkaya, Oğuz Bilal Karakuş

{"title":"Metformin usage in the treatment of risperidone induced hyperprolactinemia in an adolescent patient with bipolar disorder type 1: a case report.","authors":"Ece Topkaya, Oğuz Bilal Karakuş","doi":"10.1080/13651501.2025.2563341","DOIUrl":"10.1080/13651501.2025.2563341","url":null,"abstract":"Antipsychotic drugs are used in the treatment of many mental disorders, especially psychotic disorders, bipolar disorders and neurodevelopmental disorders in children and adolescents. Antipsychotics, along with their effectiveness in treatment, have also been associated with a number of adverse effects. One of these is hyperprolactinaemia (hyperPRL) that occurs with antipsychotics. This situation is thought to be due to dopamine blockade in the tuberoinfundibular pathway, which has an effect on prolactin release. Hereby, we present a 15 year old female adolescent bipolar disorder type 1 case who developed hyperprolactinaemia with risperidone treatment which was ameliorated with metformin use (850-2000 mg/day). Although there are studies showing that metformin can be used in the treatment of hyperprolactinaemia, as far as we know, there are not enough studies on the use of metformin in adolescents. Future studies are needed to elucidate the risk factors, aetiological mechanism and treatment alternatives of this adverse effect, which occurs due to antipsychotics and may negatively affect medication compliance.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"284-286"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0